Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals, Inc. at the 2018 Cantor Global Healthcare Conference  (Replay)
    Wednesday, October 03, 2018 11:30 am EDT
Toggle Summary Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at the APASL 2018 Annual Meeting HOPKINTON, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- Spring Bank
Toggle Summary Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference
HOPKINTON, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
Spring Bank strengthens Board of Directors with the addition of a prominent biopharma R&D veteran HOPKINTON, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic Multiple potential development catalysts and data read-outs expected in 2018 HOPKINTON, Mass.
Toggle Summary Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21
Conference Call to be Held at 8:30am Eastern Time HOPKINTON, Mass. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain
Toggle Summary Spring Bank Strengthens Management Team to Enhance Operations
Appoints Kevin Leach , Ph.D., as Vice President, Nonclinical & Translational Research Promotes Garrett Winslow to General Counsel HOPKINTON, Mass. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel
Toggle Summary Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled for Tomorrow, Nov. 16 at 8:00 a.m. EST HOPKINTON, Mass. , Nov.
Toggle Summary Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
HOPKINTON, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
Quarter highlighted by data presentations at two conferences and the initiation of research collaborations Confirms top-line results from the second inarigivir (formerly SB 9200) monotherapy dosing cohort of the ACHIEVE trial will be released in Q4 2017 HOPKINTON, Mass. , Oct.
Toggle Summary Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Inarigivir Phase 2 results confirm antiviral activity & novel mechanism of action Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial HOPKINTON, Mass. , Oct. 20, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.